SCHEMBL3882155

SCHEMBL3882155

NC(=O)c1c(Cl)ccc(Nc2c(Nc3ccc(F)cc3)c(=O)c2=O)c1O

nearest known ligand 0.77

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 15/20 0.77
CCR6 P51684 3/20 0.43
CXCR1 P25024 1/20 0.43
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882266 0.88 CXCR2 (0.66) CXCR2CCR6CXCR1
SCHEMBL3880456 0.87 CXCR2 (1.00) CXCR2CCR6CXCR1
SCHEMBL3888680 0.86 CXCR2 (0.65) CXCR2CCR6CXCR1
SCHEMBL3882238 0.84 CXCR2 (0.76) CXCR2CCR6CXCR1
SCHEMBL3881706 0.82 CXCR2 (0.73) CXCR2CCR6CXCR1
SCHEMBL3884037 0.82 CXCR2 (0.66) CXCR2CCR6
SCHEMBL3880246 0.81 CXCR2 (0.79) CXCR2CCR6CXCR1
SCHEMBL6138767 0.81 CXCR2 (0.50) CXCR2CCR6
SCHEMBL5711772 0.79 CXCR2 (0.50) CXCR2CCR6
SCHEMBL3880212 0.78 CXCR2 (0.73) CXCR2CCR6CXCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1357909-B1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2009-01-07 EP claimed
US-20060084661-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2006-04-20 US claimed
EP-1357909-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2006-01-04 EP claimed
US-20040132694-A1 Il-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2004-07-08 US claimed
EP-1357909-A1 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2003-11-05 EP claimed
WO-2002067919-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2002-09-06 WO claimed
EP-1357909-B1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2009-01-07 EP disclosed
US-20060084661-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2006-04-20 US disclosed
EP-1357909-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2006-01-04 EP disclosed
US-20040132694-A1 Il-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2004-07-08 US disclosed
EP-1357909-A1 IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2003-11-05 EP disclosed
WO-2002067919-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132694-A1 Il-8 receptor antagonists CXCL8, CCR8, TLR8 CXCR2 16/4885CCR6 50/4885CXCR1 14/4885
US-20060084661-A1 IL-8 receptor antagonists CXCL8, CCR8, TLR8 CXCR2 16/4885CCR6 50/4885CXCR1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.